AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AbbVie and other ETFs, options, and stocks.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
50,000
Employees50,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
50,000
Employees50,000

ABBV Key Statistics

Market cap
326.99B
Market cap326.99B
Price-Earnings ratio
60.81
Price-Earnings ratio60.81
Dividend yield
3.33%
Dividend yield3.33%
Average volume
5.30M
Average volume5.30M
High today
$186.85
High today$186.85
Low today
$182.17
Low today$182.17
Open price
$183.53
Open price$183.53
Volume
6.95M
Volume6.95M
52 Week high
$186.85
52 Week high$186.85
52 Week low
$135.85
52 Week low$135.85

ABBV News

Benzinga 9h
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations

On Thursday, AbbVie Inc. ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57. Net revenues reached $14...

AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
Seeking Alpha 12h
AbbVie exits Alzheimer’s program on lack of differentiation

AbbVie (NYSE:ABBV) has discontinued a Phase 2 program for its Alzheimer’s therapy, ABBV-916, citing the candidate’s lack of differentiation from the currently a...

AbbVie exits Alzheimer’s program on lack of differentiation
Reuters 20h
Q2 2024 AbbVie Inc Earnings Call

Participants Liz Shea; Investor Relations; AbbVie Inc Robert Michael; President, Chief Executive Officer, Director; AbbVie Inc Jeffrey Stewart; Executive Vic...

Q2 2024 AbbVie Inc Earnings Call

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More ABBV News

The Wall Street Journal 2d
New Drug Sales Lift AbbVie Stock

AbbVie shares rose as much as 5% early Thursday after the drugmaker said newer drugs helped soften a drop in quarterly sales from its blockbuster immunology tre...

New Drug Sales Lift AbbVie Stock
Investor's Business Daily 2d
AbbVie Is About To Have A New Golden Goose As Humira Sales Continue Slowing

AbbVie Is About To Have A New Golden Goose As Humira Sales Continue Slowing...

AbbVie Is About To Have A New Golden Goose As Humira Sales Continue Slowing
TipRanks 2d
ABBV Earnings: AbbVie Surpasses Q2 Expectations with Strong Immunology Sales

AbbVie (ABBV) reported strong results for the second quarter. The company announced adjusted diluted earnings of $2.65 per share, which is an 8.9% decrease year...

Benzinga 2d
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs

In this article: AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs On Thursday, AbbVie Inc. (NY...

AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
Seeking Alpha 2d
Cerevel ticks higher as AbbVie says it expects deal to close soon

Cerevel Therapeutics (NASDAQ:CERE) rose almost 1% in premarket trading after AbbVie (NYSE:ABBV) said it expects its planned acquisition to close soon. AbbVie (...

Cerevel ticks higher as AbbVie says it expects deal to close soon
Reuters 2d
AbbVie lifts annual profit forecast as Humira sales beat Wall Street estimates

(Reuters) — AbbVie (ABBV) raised its annual profit forecast on Thursday as strong sales of its key immunology drugs, including Humira, helped it beat Wall Stree...

AbbVie lifts annual profit forecast as Humira sales beat Wall Street estimates
TipRanks 2d
Options Volatility and Implied Earnings Moves Today, July 25, 2024

Today, several major companies are expected to report earnings: AstraZeneca (AZN), Honeywell International (HON), Royal Caribbean (RCL), Southwest Airlines (LUV...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.